nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—Sorafenib—kidney cancer	0.268	1	CrCtD
Regorafenib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.106	0.344	CiPCiCtD
Regorafenib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.0806	0.261	CiPCiCtD
Regorafenib—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0611	0.198	CiPCiCtD
Regorafenib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0611	0.198	CiPCiCtD
Regorafenib—RAF1—kidney cancer	0.0368	0.256	CbGaD
Regorafenib—FLT1—kidney cancer	0.0346	0.241	CbGaD
Regorafenib—BRAF—kidney cancer	0.0255	0.177	CbGaD
Regorafenib—KDR—kidney cancer	0.0217	0.151	CbGaD
Regorafenib—KIT—kidney cancer	0.0205	0.142	CbGaD
Regorafenib—FLT1—Pazopanib—kidney cancer	0.0111	0.0579	CbGbCtD
Regorafenib—FGFR2—Pazopanib—kidney cancer	0.00931	0.0485	CbGbCtD
Regorafenib—FGFR1—Pazopanib—kidney cancer	0.00931	0.0485	CbGbCtD
Regorafenib—FLT4—Pazopanib—kidney cancer	0.00931	0.0485	CbGbCtD
Regorafenib—MAPK11—Sorafenib—kidney cancer	0.00813	0.0423	CbGbCtD
Regorafenib—KDR—Pazopanib—kidney cancer	0.00805	0.0419	CbGbCtD
Regorafenib—EPHX2—Sorafenib—kidney cancer	0.00646	0.0336	CbGbCtD
Regorafenib—FLT1—Sorafenib—kidney cancer	0.00646	0.0336	CbGbCtD
Regorafenib—RAF1—Sorafenib—kidney cancer	0.00646	0.0336	CbGbCtD
Regorafenib—KIT—Pazopanib—kidney cancer	0.00639	0.0333	CbGbCtD
Regorafenib—PDGFRA—Pazopanib—kidney cancer	0.00639	0.0333	CbGbCtD
Regorafenib—PDGFRB—Pazopanib—kidney cancer	0.00582	0.0303	CbGbCtD
Regorafenib—FLT4—Sorafenib—kidney cancer	0.0054	0.0281	CbGbCtD
Regorafenib—BRAF—Sorafenib—kidney cancer	0.0054	0.0281	CbGbCtD
Regorafenib—FGFR1—Sorafenib—kidney cancer	0.0054	0.0281	CbGbCtD
Regorafenib—FLT1—Sunitinib—kidney cancer	0.00523	0.0272	CbGbCtD
Regorafenib—ABCB1—kidney cancer	0.00472	0.0328	CbGaD
Regorafenib—RET—Sorafenib—kidney cancer	0.00467	0.0243	CbGbCtD
Regorafenib—KDR—Sorafenib—kidney cancer	0.00467	0.0243	CbGbCtD
Regorafenib—FGFR1—Sunitinib—kidney cancer	0.00438	0.0228	CbGbCtD
Regorafenib—FLT4—Sunitinib—kidney cancer	0.00438	0.0228	CbGbCtD
Regorafenib—FGFR2—Sunitinib—kidney cancer	0.00438	0.0228	CbGbCtD
Regorafenib—NTRK1—Sunitinib—kidney cancer	0.00438	0.0228	CbGbCtD
Regorafenib—RET—Sunitinib—kidney cancer	0.00378	0.0197	CbGbCtD
Regorafenib—KDR—Sunitinib—kidney cancer	0.00378	0.0197	CbGbCtD
Regorafenib—KIT—Sorafenib—kidney cancer	0.00371	0.0193	CbGbCtD
Regorafenib—PDGFRA—Sorafenib—kidney cancer	0.00371	0.0193	CbGbCtD
Regorafenib—PDGFRB—Sorafenib—kidney cancer	0.00338	0.0176	CbGbCtD
Regorafenib—ABL1—Erlotinib—kidney cancer	0.0033	0.0172	CbGbCtD
Regorafenib—KIT—Sunitinib—kidney cancer	0.00301	0.0156	CbGbCtD
Regorafenib—PDGFRA—Sunitinib—kidney cancer	0.00301	0.0156	CbGbCtD
Regorafenib—PDGFRB—Sunitinib—kidney cancer	0.00274	0.0142	CbGbCtD
Regorafenib—UGT1A1—Pazopanib—kidney cancer	0.00192	0.00999	CbGbCtD
Regorafenib—UGT1A1—Erlotinib—kidney cancer	0.00137	0.00713	CbGbCtD
Regorafenib—UGT1A9—Sorafenib—kidney cancer	0.00136	0.00708	CbGbCtD
Regorafenib—UGT1A1—Sorafenib—kidney cancer	0.00111	0.00579	CbGbCtD
Regorafenib—ABCG2—Pazopanib—kidney cancer	0.00106	0.00549	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—kidney cancer	0.000966	0.00502	CbGbCtD
Regorafenib—ABCG2—Erlotinib—kidney cancer	0.000753	0.00392	CbGbCtD
Regorafenib—ABCB1—Temsirolimus—kidney cancer	0.000725	0.00377	CbGbCtD
Regorafenib—ABCG2—Paclitaxel—kidney cancer	0.00069	0.00359	CbGbCtD
Regorafenib—UGT1A1—urine—kidney cancer	0.000652	0.0548	CbGeAlD
Regorafenib—CYP3A4—Everolimus—kidney cancer	0.000643	0.00334	CbGbCtD
Regorafenib—ABCG2—Sorafenib—kidney cancer	0.000613	0.00319	CbGbCtD
Regorafenib—ABCG2—Vincristine—kidney cancer	0.000595	0.00309	CbGbCtD
Regorafenib—CYP2C8—Pazopanib—kidney cancer	0.000562	0.00293	CbGbCtD
Regorafenib—ABCG2—Sunitinib—kidney cancer	0.000496	0.00258	CbGbCtD
Regorafenib—CYP3A4—Temsirolimus—kidney cancer	0.000434	0.00226	CbGbCtD
Regorafenib—CYP2B6—Sorafenib—kidney cancer	0.000431	0.00224	CbGbCtD
Regorafenib—FRK—renal system—kidney cancer	0.00042	0.0353	CbGeAlD
Regorafenib—CYP2C9—Capecitabine—kidney cancer	0.000409	0.00213	CbGbCtD
Regorafenib—CYP2C8—Erlotinib—kidney cancer	0.000401	0.00209	CbGbCtD
Regorafenib—ABCB1—Pazopanib—kidney cancer	0.000381	0.00198	CbGbCtD
Regorafenib—FRK—gonad—kidney cancer	0.000377	0.0316	CbGeAlD
Regorafenib—ABCG2—Doxorubicin—kidney cancer	0.000372	0.00193	CbGbCtD
Regorafenib—CYP2C8—Paclitaxel—kidney cancer	0.000367	0.00191	CbGbCtD
Regorafenib—CYP2C19—urine—kidney cancer	0.000354	0.0297	CbGeAlD
Regorafenib—ABCB1—Dactinomycin—kidney cancer	0.000348	0.00181	CbGbCtD
Regorafenib—CYP2C8—Sorafenib—kidney cancer	0.000326	0.0017	CbGbCtD
Regorafenib—Sorafenib—RAF1—kidney cancer	0.000289	0.256	CrCbGaD
Regorafenib—EPHX2—nephron tubule—kidney cancer	0.00028	0.0235	CbGeAlD
Regorafenib—ABCB1—Gemcitabine—kidney cancer	0.000275	0.00143	CbGbCtD
Regorafenib—CYP2C9—urine—kidney cancer	0.000274	0.023	CbGeAlD
Regorafenib—CYP2C19—Sorafenib—kidney cancer	0.000274	0.00142	CbGbCtD
Regorafenib—ABCB1—Erlotinib—kidney cancer	0.000272	0.00141	CbGbCtD
Regorafenib—Sorafenib—FLT1—kidney cancer	0.000272	0.241	CrCbGaD
Regorafenib—CYP2B6—Doxorubicin—kidney cancer	0.000261	0.00136	CbGbCtD
Regorafenib—CYP2C9—Paclitaxel—kidney cancer	0.000256	0.00133	CbGbCtD
Regorafenib—ABCB1—Paclitaxel—kidney cancer	0.000249	0.00129	CbGbCtD
Regorafenib—EPHX2—cortex of kidney—kidney cancer	0.00024	0.0201	CbGeAlD
Regorafenib—UGT1A9—renal system—kidney cancer	0.000233	0.0195	CbGeAlD
Regorafenib—CYP3A4—Pazopanib—kidney cancer	0.000228	0.00119	CbGbCtD
Regorafenib—CYP2C9—Sorafenib—kidney cancer	0.000228	0.00118	CbGbCtD
Regorafenib—UGT1A9—kidney—kidney cancer	0.000225	0.0189	CbGeAlD
Regorafenib—ABCB1—Sorafenib—kidney cancer	0.000221	0.00115	CbGbCtD
Regorafenib—ABCB1—Vinblastine—kidney cancer	0.000218	0.00113	CbGbCtD
Regorafenib—FLT4—cortex of kidney—kidney cancer	0.000216	0.0182	CbGeAlD
Regorafenib—ABCB1—Vincristine—kidney cancer	0.000214	0.00112	CbGbCtD
Regorafenib—FGFR1—cortex of kidney—kidney cancer	0.000213	0.0179	CbGeAlD
Regorafenib—CYP3A4—urine—kidney cancer	0.000209	0.0175	CbGeAlD
Regorafenib—EPHA2—nephron tubule—kidney cancer	0.000208	0.0175	CbGeAlD
Regorafenib—FGFR1—cardiac atrium—kidney cancer	0.000203	0.017	CbGeAlD
Regorafenib—RET—renal system—kidney cancer	0.000203	0.017	CbGeAlD
Regorafenib—Sorafenib—BRAF—kidney cancer	0.0002	0.177	CrCbGaD
Regorafenib—FLT1—nephron tubule—kidney cancer	0.000196	0.0165	CbGeAlD
Regorafenib—RET—kidney—kidney cancer	0.000196	0.0165	CbGeAlD
Regorafenib—RAF1—nephron tubule—kidney cancer	0.000195	0.0164	CbGeAlD
Regorafenib—FGFR2—renal system—kidney cancer	0.000193	0.0162	CbGeAlD
Regorafenib—FGFR2—kidney—kidney cancer	0.000186	0.0156	CbGeAlD
Regorafenib—TEK—renal system—kidney cancer	0.000185	0.0155	CbGeAlD
Regorafenib—ABCB1—Sunitinib—kidney cancer	0.000179	0.000931	CbGbCtD
Regorafenib—FLT1—renal system—kidney cancer	0.000179	0.015	CbGeAlD
Regorafenib—TEK—kidney—kidney cancer	0.000179	0.015	CbGeAlD
Regorafenib—RAF1—renal system—kidney cancer	0.000178	0.0149	CbGeAlD
Regorafenib—TEK—cortex of kidney—kidney cancer	0.000174	0.0146	CbGeAlD
Regorafenib—FLT1—kidney—kidney cancer	0.000173	0.0145	CbGeAlD
Regorafenib—RAF1—kidney—kidney cancer	0.000172	0.0144	CbGeAlD
Regorafenib—Sorafenib—KDR—kidney cancer	0.00017	0.151	CrCbGaD
Regorafenib—EPHA2—cardiac atrium—kidney cancer	0.00017	0.0142	CbGeAlD
Regorafenib—FLT1—cortex of kidney—kidney cancer	0.000168	0.0141	CbGeAlD
Regorafenib—PDGFRA—renal system—kidney cancer	0.000167	0.014	CbGeAlD
Regorafenib—RAF1—cortex of kidney—kidney cancer	0.000167	0.014	CbGeAlD
Regorafenib—KDR—nephron tubule—kidney cancer	0.000166	0.0139	CbGeAlD
Regorafenib—TEK—cardiac atrium—kidney cancer	0.000165	0.0139	CbGeAlD
Regorafenib—CYP3A4—Erlotinib—kidney cancer	0.000163	0.000847	CbGbCtD
Regorafenib—Sorafenib—KIT—kidney cancer	0.000161	0.142	CrCbGaD
Regorafenib—FLT1—gonad—kidney cancer	0.00016	0.0134	CbGeAlD
Regorafenib—FLT1—cardiac atrium—kidney cancer	0.00016	0.0134	CbGeAlD
Regorafenib—UGT1A1—renal system—kidney cancer	0.00016	0.0134	CbGeAlD
Regorafenib—RAF1—gonad—kidney cancer	0.000159	0.0134	CbGeAlD
Regorafenib—RAF1—cardiac atrium—kidney cancer	0.000159	0.0133	CbGeAlD
Regorafenib—UGT1A1—kidney—kidney cancer	0.000154	0.013	CbGeAlD
Regorafenib—KDR—renal system—kidney cancer	0.000151	0.0127	CbGeAlD
Regorafenib—PDGFRA—gonad—kidney cancer	0.00015	0.0126	CbGeAlD
Regorafenib—CYP3A4—Paclitaxel—kidney cancer	0.000149	0.000775	CbGbCtD
Regorafenib—KIT—nephron tubule—kidney cancer	0.000147	0.0124	CbGeAlD
Regorafenib—KDR—kidney—kidney cancer	0.000146	0.0122	CbGeAlD
Regorafenib—KDR—cortex of kidney—kidney cancer	0.000142	0.0119	CbGeAlD
Regorafenib—KDR—cardiac atrium—kidney cancer	0.000135	0.0113	CbGeAlD
Regorafenib—ABCB1—Doxorubicin—kidney cancer	0.000134	0.000697	CbGbCtD
Regorafenib—KIT—renal system—kidney cancer	0.000134	0.0112	CbGeAlD
Regorafenib—CYP3A4—Sorafenib—kidney cancer	0.000132	0.000689	CbGbCtD
Regorafenib—PDGFRB—renal system—kidney cancer	0.000131	0.011	CbGeAlD
Regorafenib—CYP3A4—Vinblastine—kidney cancer	0.000131	0.00068	CbGbCtD
Regorafenib—KIT—kidney—kidney cancer	0.000129	0.0109	CbGeAlD
Regorafenib—CYP3A4—Vincristine—kidney cancer	0.000128	0.000668	CbGbCtD
Regorafenib—ABL1—nephron tubule—kidney cancer	0.000128	0.0108	CbGeAlD
Regorafenib—PDGFRB—kidney—kidney cancer	0.000126	0.0106	CbGeAlD
Regorafenib—KIT—cortex of kidney—kidney cancer	0.000126	0.0106	CbGeAlD
Regorafenib—PDGFRB—cortex of kidney—kidney cancer	0.000123	0.0103	CbGeAlD
Regorafenib—KIT—gonad—kidney cancer	0.00012	0.0101	CbGeAlD
Regorafenib—PDGFRB—gonad—kidney cancer	0.000117	0.00983	CbGeAlD
Regorafenib—PDGFRB—cardiac atrium—kidney cancer	0.000117	0.00982	CbGeAlD
Regorafenib—ABL1—renal system—kidney cancer	0.000116	0.00977	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—kidney cancer	0.000114	0.333	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—kidney cancer	0.000114	0.333	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	0.000114	0.333	CbGdCrCtD
Regorafenib—ABL1—kidney—kidney cancer	0.000113	0.00945	CbGeAlD
Regorafenib—ABL1—cortex of kidney—kidney cancer	0.00011	0.0092	CbGeAlD
Regorafenib—CYP3A4—Sunitinib—kidney cancer	0.000107	0.000558	CbGbCtD
Regorafenib—ABL1—gonad—kidney cancer	0.000104	0.00877	CbGeAlD
Regorafenib—ABL1—cardiac atrium—kidney cancer	0.000104	0.00875	CbGeAlD
Regorafenib—ABCG2—nephron tubule—kidney cancer	8.08e-05	0.00678	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—kidney cancer	8.03e-05	0.000418	CbGbCtD
Regorafenib—CYP2C8—renal system—kidney cancer	7.55e-05	0.00634	CbGeAlD
Regorafenib—CYP2B6—nephron tubule—kidney cancer	7.45e-05	0.00626	CbGeAlD
Regorafenib—CYP2C8—kidney—kidney cancer	7.3e-05	0.00613	CbGeAlD
Regorafenib—CYP2B6—renal system—kidney cancer	6.78e-05	0.00569	CbGeAlD
Regorafenib—CYP2B6—kidney—kidney cancer	6.55e-05	0.0055	CbGeAlD
Regorafenib—CYP2B6—gonad—kidney cancer	6.08e-05	0.0051	CbGeAlD
Regorafenib—CYP3A4—renal system—kidney cancer	5.12e-05	0.00429	CbGeAlD
Regorafenib—CYP3A4—kidney—kidney cancer	4.95e-05	0.00415	CbGeAlD
Regorafenib—ABCB1—nephron tubule—kidney cancer	3.98e-05	0.00334	CbGeAlD
Regorafenib—Sorafenib—ABCB1—kidney cancer	3.7e-05	0.0328	CrCbGaD
Regorafenib—ABCB1—renal system—kidney cancer	3.62e-05	0.00304	CbGeAlD
Regorafenib—ABCB1—kidney—kidney cancer	3.5e-05	0.00294	CbGeAlD
Regorafenib—ABCB1—cortex of kidney—kidney cancer	3.41e-05	0.00286	CbGeAlD
Regorafenib—ABCB1—gonad—kidney cancer	3.25e-05	0.00273	CbGeAlD
Regorafenib—Gastrointestinal disorder—Erlotinib—kidney cancer	2.44e-05	0.000631	CcSEcCtD
Regorafenib—Hepatobiliary disease—Paclitaxel—kidney cancer	2.44e-05	0.00063	CcSEcCtD
Regorafenib—Fatigue—Erlotinib—kidney cancer	2.44e-05	0.00063	CcSEcCtD
Regorafenib—Infection—Sunitinib—kidney cancer	2.43e-05	0.000629	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Capecitabine—kidney cancer	2.42e-05	0.000626	CcSEcCtD
Regorafenib—Pain—Erlotinib—kidney cancer	2.42e-05	0.000625	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vinblastine—kidney cancer	2.41e-05	0.000622	CcSEcCtD
Regorafenib—Nervous system disorder—Sunitinib—kidney cancer	2.4e-05	0.00062	CcSEcCtD
Regorafenib—Thrombocytopenia—Sunitinib—kidney cancer	2.4e-05	0.000619	CcSEcCtD
Regorafenib—Gastrointestinal pain—Everolimus—kidney cancer	2.4e-05	0.000619	CcSEcCtD
Regorafenib—Skin disorder—Sunitinib—kidney cancer	2.38e-05	0.000615	CcSEcCtD
Regorafenib—Vomiting—Pazopanib—kidney cancer	2.36e-05	0.00061	CcSEcCtD
Regorafenib—Anaemia—Vincristine—kidney cancer	2.34e-05	0.000606	CcSEcCtD
Regorafenib—Rash—Pazopanib—kidney cancer	2.34e-05	0.000605	CcSEcCtD
Regorafenib—Nausea—Temsirolimus—kidney cancer	2.34e-05	0.000605	CcSEcCtD
Regorafenib—Dermatitis—Pazopanib—kidney cancer	2.34e-05	0.000604	CcSEcCtD
Regorafenib—Haemoglobin—Paclitaxel—kidney cancer	2.33e-05	0.000601	CcSEcCtD
Regorafenib—Abdominal pain—Vinblastine—kidney cancer	2.33e-05	0.000601	CcSEcCtD
Regorafenib—Headache—Pazopanib—kidney cancer	2.32e-05	0.000601	CcSEcCtD
Regorafenib—Body temperature increased—Everolimus—kidney cancer	2.32e-05	0.000599	CcSEcCtD
Regorafenib—Abdominal pain—Everolimus—kidney cancer	2.32e-05	0.000599	CcSEcCtD
Regorafenib—Haemorrhage—Paclitaxel—kidney cancer	2.31e-05	0.000598	CcSEcCtD
Regorafenib—Gastrointestinal pain—Erlotinib—kidney cancer	2.31e-05	0.000598	CcSEcCtD
Regorafenib—Infection—Dactinomycin—kidney cancer	2.3e-05	0.000595	CcSEcCtD
Regorafenib—Urinary tract disorder—Paclitaxel—kidney cancer	2.29e-05	0.000591	CcSEcCtD
Regorafenib—Connective tissue disorder—Paclitaxel—kidney cancer	2.27e-05	0.000588	CcSEcCtD
Regorafenib—Leukopenia—Vincristine—kidney cancer	2.27e-05	0.000587	CcSEcCtD
Regorafenib—Urethral disorder—Paclitaxel—kidney cancer	2.27e-05	0.000586	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—kidney cancer	2.27e-05	0.000586	CcSEcCtD
Regorafenib—Abdominal pain—Erlotinib—kidney cancer	2.23e-05	0.000578	CcSEcCtD
Regorafenib—Body temperature increased—Erlotinib—kidney cancer	2.23e-05	0.000578	CcSEcCtD
Regorafenib—Anaemia—Gemcitabine—kidney cancer	2.22e-05	0.000575	CcSEcCtD
Regorafenib—Neutropenia—Capecitabine—kidney cancer	2.22e-05	0.000574	CcSEcCtD
Regorafenib—Decreased appetite—Sorafenib—kidney cancer	2.21e-05	0.000572	CcSEcCtD
Regorafenib—Nausea—Pazopanib—kidney cancer	2.2e-05	0.00057	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—kidney cancer	2.2e-05	0.00057	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Sorafenib—kidney cancer	2.2e-05	0.000568	CcSEcCtD
Regorafenib—Fatigue—Sorafenib—kidney cancer	2.19e-05	0.000567	CcSEcCtD
Regorafenib—Hypertension—Vincristine—kidney cancer	2.19e-05	0.000566	CcSEcCtD
Regorafenib—Erythema multiforme—Paclitaxel—kidney cancer	2.19e-05	0.000566	CcSEcCtD
Regorafenib—Pain—Sorafenib—kidney cancer	2.17e-05	0.000562	CcSEcCtD
Regorafenib—Leukopenia—Gemcitabine—kidney cancer	2.15e-05	0.000557	CcSEcCtD
Regorafenib—Cardiac disorder—Paclitaxel—kidney cancer	2.15e-05	0.000555	CcSEcCtD
Regorafenib—Weight decreased—Capecitabine—kidney cancer	2.15e-05	0.000555	CcSEcCtD
Regorafenib—Decreased appetite—Sunitinib—kidney cancer	2.13e-05	0.00055	CcSEcCtD
Regorafenib—Infestation NOS—Capecitabine—kidney cancer	2.12e-05	0.000547	CcSEcCtD
Regorafenib—Infestation—Capecitabine—kidney cancer	2.12e-05	0.000547	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Sunitinib—kidney cancer	2.11e-05	0.000546	CcSEcCtD
Regorafenib—Asthenia—Vinblastine—kidney cancer	2.11e-05	0.000546	CcSEcCtD
Regorafenib—Fatigue—Sunitinib—kidney cancer	2.11e-05	0.000545	CcSEcCtD
Regorafenib—Asthenia—Everolimus—kidney cancer	2.1e-05	0.000543	CcSEcCtD
Regorafenib—Angiopathy—Paclitaxel—kidney cancer	2.1e-05	0.000543	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Capecitabine—kidney cancer	2.1e-05	0.000542	CcSEcCtD
Regorafenib—Pain—Sunitinib—kidney cancer	2.09e-05	0.000541	CcSEcCtD
Regorafenib—Mediastinal disorder—Paclitaxel—kidney cancer	2.09e-05	0.000539	CcSEcCtD
Regorafenib—Acute coronary syndrome—Capecitabine—kidney cancer	2.09e-05	0.000539	CcSEcCtD
Regorafenib—Gastrointestinal pain—Sorafenib—kidney cancer	2.08e-05	0.000538	CcSEcCtD
Regorafenib—Hypertension—Gemcitabine—kidney cancer	2.08e-05	0.000537	CcSEcCtD
Regorafenib—Myocardial infarction—Capecitabine—kidney cancer	2.07e-05	0.000536	CcSEcCtD
Regorafenib—Stomatitis—Capecitabine—kidney cancer	2.06e-05	0.000533	CcSEcCtD
Regorafenib—Infection—Vincristine—kidney cancer	2.06e-05	0.000532	CcSEcCtD
Regorafenib—Alopecia—Paclitaxel—kidney cancer	2.04e-05	0.000529	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	2.03e-05	0.000526	CcSEcCtD
Regorafenib—Nervous system disorder—Vincristine—kidney cancer	2.03e-05	0.000525	CcSEcCtD
Regorafenib—Asthenia—Erlotinib—kidney cancer	2.03e-05	0.000524	CcSEcCtD
Regorafenib—Thrombocytopenia—Vincristine—kidney cancer	2.03e-05	0.000524	CcSEcCtD
Regorafenib—Malnutrition—Paclitaxel—kidney cancer	2.01e-05	0.000521	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—kidney cancer	2.01e-05	0.000521	CcSEcCtD
Regorafenib—Diarrhoea—Vinblastine—kidney cancer	2.01e-05	0.00052	CcSEcCtD
Regorafenib—Abdominal pain—Sorafenib—kidney cancer	2.01e-05	0.00052	CcSEcCtD
Regorafenib—Body temperature increased—Sorafenib—kidney cancer	2.01e-05	0.00052	CcSEcCtD
Regorafenib—Diarrhoea—Everolimus—kidney cancer	2e-05	0.000518	CcSEcCtD
Regorafenib—Gastrointestinal pain—Sunitinib—kidney cancer	2e-05	0.000517	CcSEcCtD
Regorafenib—Hepatobiliary disease—Capecitabine—kidney cancer	2e-05	0.000517	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—kidney cancer	2e-05	0.000516	CcSEcCtD
Regorafenib—Pain—Dactinomycin—kidney cancer	1.98e-05	0.000512	CcSEcCtD
Regorafenib—Infection—Gemcitabine—kidney cancer	1.95e-05	0.000504	CcSEcCtD
Regorafenib—Body temperature increased—Sunitinib—kidney cancer	1.93e-05	0.0005	CcSEcCtD
Regorafenib—Abdominal pain—Sunitinib—kidney cancer	1.93e-05	0.0005	CcSEcCtD
Regorafenib—Diarrhoea—Erlotinib—kidney cancer	1.93e-05	0.0005	CcSEcCtD
Regorafenib—Nervous system disorder—Gemcitabine—kidney cancer	1.93e-05	0.000498	CcSEcCtD
Regorafenib—Thrombocytopenia—Gemcitabine—kidney cancer	1.92e-05	0.000497	CcSEcCtD
Regorafenib—Haemoglobin—Capecitabine—kidney cancer	1.91e-05	0.000493	CcSEcCtD
Regorafenib—Skin disorder—Gemcitabine—kidney cancer	1.91e-05	0.000493	CcSEcCtD
Regorafenib—Haemorrhage—Capecitabine—kidney cancer	1.9e-05	0.000491	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—kidney cancer	1.89e-05	0.00049	CcSEcCtD
Regorafenib—Tremor—Paclitaxel—kidney cancer	1.89e-05	0.000488	CcSEcCtD
Regorafenib—Urinary tract disorder—Capecitabine—kidney cancer	1.88e-05	0.000485	CcSEcCtD
Regorafenib—Vomiting—Vinblastine—kidney cancer	1.87e-05	0.000483	CcSEcCtD
Regorafenib—Connective tissue disorder—Capecitabine—kidney cancer	1.87e-05	0.000482	CcSEcCtD
Regorafenib—Vomiting—Everolimus—kidney cancer	1.86e-05	0.000482	CcSEcCtD
Regorafenib—Anaemia—Paclitaxel—kidney cancer	1.86e-05	0.000481	CcSEcCtD
Regorafenib—Urethral disorder—Capecitabine—kidney cancer	1.86e-05	0.000481	CcSEcCtD
Regorafenib—Rash—Everolimus—kidney cancer	1.85e-05	0.000478	CcSEcCtD
Regorafenib—Dermatitis—Everolimus—kidney cancer	1.85e-05	0.000477	CcSEcCtD
Regorafenib—Headache—Vinblastine—kidney cancer	1.84e-05	0.000476	CcSEcCtD
Regorafenib—Headache—Everolimus—kidney cancer	1.84e-05	0.000474	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—kidney cancer	1.83e-05	0.000473	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—kidney cancer	1.83e-05	0.000473	CcSEcCtD
Regorafenib—Asthenia—Sorafenib—kidney cancer	1.82e-05	0.000472	CcSEcCtD
Regorafenib—Leukopenia—Paclitaxel—kidney cancer	1.8e-05	0.000466	CcSEcCtD
Regorafenib—Decreased appetite—Vincristine—kidney cancer	1.8e-05	0.000465	CcSEcCtD
Regorafenib—Vomiting—Erlotinib—kidney cancer	1.8e-05	0.000465	CcSEcCtD
Regorafenib—Erythema multiforme—Capecitabine—kidney cancer	1.8e-05	0.000464	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vincristine—kidney cancer	1.79e-05	0.000462	CcSEcCtD
Regorafenib—Fatigue—Vincristine—kidney cancer	1.78e-05	0.000461	CcSEcCtD
Regorafenib—Rash—Erlotinib—kidney cancer	1.78e-05	0.000461	CcSEcCtD
Regorafenib—Dermatitis—Erlotinib—kidney cancer	1.78e-05	0.00046	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—kidney cancer	1.78e-05	0.000459	CcSEcCtD
Regorafenib—Headache—Erlotinib—kidney cancer	1.77e-05	0.000458	CcSEcCtD
Regorafenib—Pain—Vincristine—kidney cancer	1.77e-05	0.000458	CcSEcCtD
Regorafenib—Cardiac disorder—Capecitabine—kidney cancer	1.76e-05	0.000456	CcSEcCtD
Regorafenib—Asthenia—Sunitinib—kidney cancer	1.76e-05	0.000454	CcSEcCtD
Regorafenib—Nausea—Vinblastine—kidney cancer	1.75e-05	0.000452	CcSEcCtD
Regorafenib—Nausea—Everolimus—kidney cancer	1.74e-05	0.00045	CcSEcCtD
Regorafenib—Diarrhoea—Sorafenib—kidney cancer	1.74e-05	0.00045	CcSEcCtD
Regorafenib—Hypertension—Paclitaxel—kidney cancer	1.74e-05	0.00045	CcSEcCtD
Regorafenib—Angiopathy—Capecitabine—kidney cancer	1.72e-05	0.000445	CcSEcCtD
Regorafenib—Mediastinal disorder—Capecitabine—kidney cancer	1.71e-05	0.000442	CcSEcCtD
Regorafenib—Decreased appetite—Gemcitabine—kidney cancer	1.71e-05	0.000441	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	1.7e-05	0.00044	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Gemcitabine—kidney cancer	1.7e-05	0.000438	CcSEcCtD
Regorafenib—Fatigue—Gemcitabine—kidney cancer	1.69e-05	0.000438	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vincristine—kidney cancer	1.69e-05	0.000438	CcSEcCtD
Regorafenib—Pain—Gemcitabine—kidney cancer	1.68e-05	0.000434	CcSEcCtD
Regorafenib—Nausea—Erlotinib—kidney cancer	1.68e-05	0.000434	CcSEcCtD
Regorafenib—Alopecia—Capecitabine—kidney cancer	1.68e-05	0.000434	CcSEcCtD
Regorafenib—Dry mouth—Paclitaxel—kidney cancer	1.68e-05	0.000434	CcSEcCtD
Regorafenib—Diarrhoea—Sunitinib—kidney cancer	1.67e-05	0.000433	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—kidney cancer	1.66e-05	0.00043	CcSEcCtD
Regorafenib—Malnutrition—Capecitabine—kidney cancer	1.65e-05	0.000427	CcSEcCtD
Regorafenib—Abdominal pain—Vincristine—kidney cancer	1.64e-05	0.000423	CcSEcCtD
Regorafenib—Body temperature increased—Vincristine—kidney cancer	1.64e-05	0.000423	CcSEcCtD
Regorafenib—Infection—Paclitaxel—kidney cancer	1.63e-05	0.000422	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—kidney cancer	1.62e-05	0.000419	CcSEcCtD
Regorafenib—Vomiting—Sorafenib—kidney cancer	1.62e-05	0.000418	CcSEcCtD
Regorafenib—Nervous system disorder—Paclitaxel—kidney cancer	1.61e-05	0.000417	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—kidney cancer	1.61e-05	0.000416	CcSEcCtD
Regorafenib—Thrombocytopenia—Paclitaxel—kidney cancer	1.61e-05	0.000416	CcSEcCtD
Regorafenib—Rash—Sorafenib—kidney cancer	1.6e-05	0.000415	CcSEcCtD
Regorafenib—Dermatitis—Sorafenib—kidney cancer	1.6e-05	0.000414	CcSEcCtD
Regorafenib—Skin disorder—Paclitaxel—kidney cancer	1.6e-05	0.000413	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	1.59e-05	0.000412	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	1.59e-05	0.000412	CcSEcCtD
Regorafenib—Headache—Sorafenib—kidney cancer	1.59e-05	0.000412	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—kidney cancer	1.59e-05	0.00041	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	1.56e-05	0.000403	CcSEcCtD
Regorafenib—Vomiting—Sunitinib—kidney cancer	1.56e-05	0.000402	CcSEcCtD
Regorafenib—Body temperature increased—Gemcitabine—kidney cancer	1.55e-05	0.000401	CcSEcCtD
Regorafenib—Tremor—Capecitabine—kidney cancer	1.55e-05	0.0004	CcSEcCtD
Regorafenib—Rash—Sunitinib—kidney cancer	1.54e-05	0.000399	CcSEcCtD
Regorafenib—Dermatitis—Sunitinib—kidney cancer	1.54e-05	0.000399	CcSEcCtD
Regorafenib—Headache—Sunitinib—kidney cancer	1.53e-05	0.000396	CcSEcCtD
Regorafenib—Anaemia—Capecitabine—kidney cancer	1.53e-05	0.000395	CcSEcCtD
Regorafenib—Nausea—Sorafenib—kidney cancer	1.51e-05	0.000391	CcSEcCtD
Regorafenib—Asthenia—Vincristine—kidney cancer	1.49e-05	0.000384	CcSEcCtD
Regorafenib—Leukopenia—Capecitabine—kidney cancer	1.48e-05	0.000383	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—kidney cancer	1.47e-05	0.000381	CcSEcCtD
Regorafenib—Rash—Dactinomycin—kidney cancer	1.46e-05	0.000378	CcSEcCtD
Regorafenib—Nausea—Sunitinib—kidney cancer	1.45e-05	0.000376	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—kidney cancer	1.43e-05	0.00037	CcSEcCtD
Regorafenib—Decreased appetite—Paclitaxel—kidney cancer	1.43e-05	0.000369	CcSEcCtD
Regorafenib—Hypertension—Capecitabine—kidney cancer	1.43e-05	0.000369	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.42e-05	0.000367	CcSEcCtD
Regorafenib—Fatigue—Paclitaxel—kidney cancer	1.42e-05	0.000366	CcSEcCtD
Regorafenib—Diarrhoea—Vincristine—kidney cancer	1.42e-05	0.000366	CcSEcCtD
Regorafenib—Asthenia—Gemcitabine—kidney cancer	1.41e-05	0.000364	CcSEcCtD
Regorafenib—Pain—Paclitaxel—kidney cancer	1.41e-05	0.000363	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.4e-05	0.000361	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—kidney cancer	1.38e-05	0.000358	CcSEcCtD
Regorafenib—Dry mouth—Capecitabine—kidney cancer	1.38e-05	0.000356	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—kidney cancer	1.38e-05	0.000356	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—kidney cancer	1.36e-05	0.000353	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—kidney cancer	1.36e-05	0.000353	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	1.35e-05	0.000349	CcSEcCtD
Regorafenib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.34e-05	0.000348	CcSEcCtD
Regorafenib—Diarrhoea—Gemcitabine—kidney cancer	1.34e-05	0.000347	CcSEcCtD
Regorafenib—Infection—Capecitabine—kidney cancer	1.34e-05	0.000347	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—kidney cancer	1.33e-05	0.000344	CcSEcCtD
Regorafenib—Nervous system disorder—Capecitabine—kidney cancer	1.32e-05	0.000342	CcSEcCtD
Regorafenib—Thrombocytopenia—Capecitabine—kidney cancer	1.32e-05	0.000341	CcSEcCtD
Regorafenib—Vomiting—Vincristine—kidney cancer	1.32e-05	0.00034	CcSEcCtD
Regorafenib—Skin disorder—Capecitabine—kidney cancer	1.31e-05	0.000339	CcSEcCtD
Regorafenib—Rash—Vincristine—kidney cancer	1.31e-05	0.000337	CcSEcCtD
Regorafenib—Dermatitis—Vincristine—kidney cancer	1.3e-05	0.000337	CcSEcCtD
Regorafenib—Abdominal pain—Paclitaxel—kidney cancer	1.3e-05	0.000336	CcSEcCtD
Regorafenib—Body temperature increased—Paclitaxel—kidney cancer	1.3e-05	0.000336	CcSEcCtD
Regorafenib—Headache—Vincristine—kidney cancer	1.3e-05	0.000335	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.29e-05	0.000333	CcSEcCtD
Regorafenib—Vomiting—Gemcitabine—kidney cancer	1.25e-05	0.000323	CcSEcCtD
Regorafenib—Rash—Gemcitabine—kidney cancer	1.24e-05	0.00032	CcSEcCtD
Regorafenib—Dermatitis—Gemcitabine—kidney cancer	1.24e-05	0.00032	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—kidney cancer	1.23e-05	0.000318	CcSEcCtD
Regorafenib—Headache—Gemcitabine—kidney cancer	1.23e-05	0.000318	CcSEcCtD
Regorafenib—Nausea—Vincristine—kidney cancer	1.23e-05	0.000318	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—kidney cancer	1.22e-05	0.000316	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—kidney cancer	1.21e-05	0.000313	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—kidney cancer	1.2e-05	0.000311	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—kidney cancer	1.2e-05	0.00031	CcSEcCtD
Regorafenib—Asthenia—Paclitaxel—kidney cancer	1.18e-05	0.000305	CcSEcCtD
Regorafenib—Decreased appetite—Capecitabine—kidney cancer	1.17e-05	0.000303	CcSEcCtD
Regorafenib—Nausea—Gemcitabine—kidney cancer	1.17e-05	0.000302	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.16e-05	0.000301	CcSEcCtD
Regorafenib—Fatigue—Capecitabine—kidney cancer	1.16e-05	0.000301	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—kidney cancer	1.16e-05	0.000299	CcSEcCtD
Regorafenib—Pain—Capecitabine—kidney cancer	1.15e-05	0.000298	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—kidney cancer	1.14e-05	0.000294	CcSEcCtD
Regorafenib—Diarrhoea—Paclitaxel—kidney cancer	1.12e-05	0.000291	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—kidney cancer	1.11e-05	0.000287	CcSEcCtD
Regorafenib—Gastrointestinal pain—Capecitabine—kidney cancer	1.1e-05	0.000285	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—kidney cancer	1.1e-05	0.000285	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—kidney cancer	1.08e-05	0.00028	CcSEcCtD
Regorafenib—Abdominal pain—Capecitabine—kidney cancer	1.07e-05	0.000276	CcSEcCtD
Regorafenib—Body temperature increased—Capecitabine—kidney cancer	1.07e-05	0.000276	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—kidney cancer	1.07e-05	0.000275	CcSEcCtD
Regorafenib—Vomiting—Paclitaxel—kidney cancer	1.05e-05	0.00027	CcSEcCtD
Regorafenib—Rash—Paclitaxel—kidney cancer	1.04e-05	0.000268	CcSEcCtD
Regorafenib—Dermatitis—Paclitaxel—kidney cancer	1.04e-05	0.000268	CcSEcCtD
Regorafenib—Headache—Paclitaxel—kidney cancer	1.03e-05	0.000266	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—kidney cancer	9.85e-06	0.000255	CcSEcCtD
Regorafenib—Nausea—Paclitaxel—kidney cancer	9.77e-06	0.000252	CcSEcCtD
Regorafenib—Asthenia—Capecitabine—kidney cancer	9.68e-06	0.00025	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—kidney cancer	9.54e-06	0.000247	CcSEcCtD
Regorafenib—Diarrhoea—Capecitabine—kidney cancer	9.23e-06	0.000239	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—kidney cancer	9.2e-06	0.000238	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	9.01e-06	0.000233	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—kidney cancer	8.87e-06	0.000229	CcSEcCtD
Regorafenib—Infection—Doxorubicin—kidney cancer	8.64e-06	0.000223	CcSEcCtD
Regorafenib—Vomiting—Capecitabine—kidney cancer	8.58e-06	0.000222	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—kidney cancer	8.53e-06	0.00022	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—kidney cancer	8.51e-06	0.00022	CcSEcCtD
Regorafenib—Rash—Capecitabine—kidney cancer	8.51e-06	0.00022	CcSEcCtD
Regorafenib—Dermatitis—Capecitabine—kidney cancer	8.5e-06	0.00022	CcSEcCtD
Regorafenib—Headache—Capecitabine—kidney cancer	8.45e-06	0.000218	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—kidney cancer	8.45e-06	0.000218	CcSEcCtD
Regorafenib—Nausea—Capecitabine—kidney cancer	8.01e-06	0.000207	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—kidney cancer	7.56e-06	0.000195	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.51e-06	0.000194	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—kidney cancer	7.5e-06	0.000194	CcSEcCtD
Regorafenib—Pain—Doxorubicin—kidney cancer	7.44e-06	0.000192	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—kidney cancer	7.11e-06	0.000184	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—kidney cancer	6.87e-06	0.000178	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—kidney cancer	6.87e-06	0.000178	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—kidney cancer	6.24e-06	0.000161	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—kidney cancer	5.95e-06	0.000154	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—kidney cancer	5.53e-06	0.000143	CcSEcCtD
Regorafenib—Rash—Doxorubicin—kidney cancer	5.48e-06	0.000142	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—kidney cancer	5.48e-06	0.000142	CcSEcCtD
Regorafenib—Headache—Doxorubicin—kidney cancer	5.45e-06	0.000141	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—kidney cancer	5.17e-06	0.000134	CcSEcCtD
Regorafenib—ABCG2—Metabolism—POMC—kidney cancer	3.98e-07	1.16e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCND1—kidney cancer	3.97e-07	1.16e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CTNNB1—kidney cancer	3.97e-07	1.16e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC2A1—kidney cancer	3.97e-07	1.16e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JUN—kidney cancer	3.97e-07	1.16e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—kidney cancer	3.96e-07	1.16e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.95e-07	1.15e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CTNNB1—kidney cancer	3.94e-07	1.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KRAS—kidney cancer	3.93e-07	1.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MAPK3—kidney cancer	3.93e-07	1.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—kidney cancer	3.93e-07	1.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—RAF1—kidney cancer	3.93e-07	1.15e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KRAS—kidney cancer	3.92e-07	1.15e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—kidney cancer	3.92e-07	1.15e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—RAF1—kidney cancer	3.92e-07	1.15e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP1A1—kidney cancer	3.91e-07	1.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—RELA—kidney cancer	3.91e-07	1.14e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—RELA—kidney cancer	3.9e-07	1.14e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KRAS—kidney cancer	3.9e-07	1.14e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—BCHE—kidney cancer	3.89e-07	1.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CTNNB1—kidney cancer	3.89e-07	1.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ERBB2—kidney cancer	3.89e-07	1.14e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—PIK3CA—kidney cancer	3.88e-07	1.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ERBB2—kidney cancer	3.88e-07	1.13e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MAPK1—kidney cancer	3.87e-07	1.13e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTEN—kidney cancer	3.87e-07	1.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PIK3CA—kidney cancer	3.86e-07	1.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CDKN1B—kidney cancer	3.86e-07	1.13e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.86e-07	1.13e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MAPK3—kidney cancer	3.85e-07	1.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MAPK1—kidney cancer	3.85e-07	1.12e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC5A5—kidney cancer	3.84e-07	1.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—MAPK3—kidney cancer	3.84e-07	1.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MAPK1—kidney cancer	3.84e-07	1.12e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTEN—kidney cancer	3.84e-07	1.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MAPK3—kidney cancer	3.83e-07	1.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MTOR—kidney cancer	3.83e-07	1.12e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—KRAS—kidney cancer	3.83e-07	1.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MTOR—kidney cancer	3.82e-07	1.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—POMC—kidney cancer	3.81e-07	1.12e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—PIK3CA—kidney cancer	3.81e-07	1.11e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTP1—kidney cancer	3.8e-07	1.11e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CDKN1B—kidney cancer	3.79e-07	1.11e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTEN—kidney cancer	3.79e-07	1.11e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.79e-07	1.11e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—kidney cancer	3.78e-07	1.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—BRAF—kidney cancer	3.77e-07	1.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MAPK1—kidney cancer	3.74e-07	1.09e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—kidney cancer	3.74e-07	1.09e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—kidney cancer	3.74e-07	1.09e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—kidney cancer	3.74e-07	1.09e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—kidney cancer	3.71e-07	1.08e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.71e-07	1.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCND1—kidney cancer	3.68e-07	1.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JUN—kidney cancer	3.68e-07	1.07e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MAPK1—kidney cancer	3.66e-07	1.07e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KRAS—kidney cancer	3.66e-07	1.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—MAPK1—kidney cancer	3.65e-07	1.07e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MAPK1—kidney cancer	3.65e-07	1.07e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CTNNB1—kidney cancer	3.65e-07	1.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KRAS—kidney cancer	3.63e-07	1.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MAPK3—kidney cancer	3.63e-07	1.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KRAS—kidney cancer	3.62e-07	1.06e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCND1—kidney cancer	3.62e-07	1.06e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—PIK3CA—kidney cancer	3.62e-07	1.06e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JUN—kidney cancer	3.61e-07	1.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—PIK3CA—kidney cancer	3.61e-07	1.05e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.6e-07	1.05e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ABCB1—kidney cancer	3.6e-07	1.05e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CDKN1B—kidney cancer	3.6e-07	1.05e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CDKN1B—kidney cancer	3.59e-07	1.05e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CTNNB1—kidney cancer	3.58e-07	1.05e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PIK3CA—kidney cancer	3.58e-07	1.05e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTEN—kidney cancer	3.55e-07	1.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KRAS—kidney cancer	3.54e-07	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—kidney cancer	3.53e-07	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	3.53e-07	1.03e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—kidney cancer	3.52e-07	1.03e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PIK3CA—kidney cancer	3.52e-07	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RELA—kidney cancer	3.51e-07	1.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—kidney cancer	3.51e-07	1.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MAPK3—kidney cancer	3.51e-07	1.03e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—kidney cancer	3.5e-07	1.02e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTM1—kidney cancer	3.49e-07	1.02e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	3.49e-07	1.02e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTEN—kidney cancer	3.49e-07	1.02e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CRABP1—kidney cancer	3.47e-07	1.02e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—kidney cancer	3.46e-07	1.01e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KRAS—kidney cancer	3.46e-07	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MAPK1—kidney cancer	3.46e-07	1.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—KRAS—kidney cancer	3.45e-07	1.01e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KRAS—kidney cancer	3.45e-07	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	3.45e-07	1.01e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.44e-07	1.01e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCND1—kidney cancer	3.43e-07	1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—kidney cancer	3.43e-07	1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	3.42e-07	1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—kidney cancer	3.42e-07	9.99e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CTNNB1—kidney cancer	3.4e-07	9.94e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTP1—kidney cancer	3.39e-07	9.92e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	3.39e-07	9.91e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PIK3CA—kidney cancer	3.36e-07	9.83e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PIK3CA—kidney cancer	3.34e-07	9.76e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MAPK1—kidney cancer	3.34e-07	9.76e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PIK3CA—kidney cancer	3.33e-07	9.73e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTEN—kidney cancer	3.31e-07	9.69e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTP1—kidney cancer	3.31e-07	9.69e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP1A1—kidney cancer	3.31e-07	9.68e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK3—kidney cancer	3.31e-07	9.67e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	3.3e-07	9.66e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK3—kidney cancer	3.28e-07	9.58e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—kidney cancer	3.26e-07	9.55e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTEN—kidney cancer	3.26e-07	9.54e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTEN—kidney cancer	3.26e-07	9.54e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—kidney cancer	3.25e-07	9.51e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PIK3CA—kidney cancer	3.25e-07	9.5e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK3—kidney cancer	3.24e-07	9.47e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	3.23e-07	9.45e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ITPR2—kidney cancer	3.23e-07	9.44e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—kidney cancer	3.22e-07	9.41e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCB1—kidney cancer	3.21e-07	9.39e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—kidney cancer	3.21e-07	9.39e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—kidney cancer	3.19e-07	9.32e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—kidney cancer	3.18e-07	9.29e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—kidney cancer	3.17e-07	9.28e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—kidney cancer	3.17e-07	9.27e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—kidney cancer	3.17e-07	9.26e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—kidney cancer	3.16e-07	9.25e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—kidney cancer	3.15e-07	9.22e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—kidney cancer	3.15e-07	9.22e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—kidney cancer	3.15e-07	9.21e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK1—kidney cancer	3.15e-07	9.2e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.14e-07	9.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RELA—kidney cancer	3.13e-07	9.16e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTM1—kidney cancer	3.12e-07	9.12e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK1—kidney cancer	3.12e-07	9.12e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—kidney cancer	3.11e-07	9.1e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTP1—kidney cancer	3.09e-07	9.05e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	3.08e-07	9.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK1—kidney cancer	3.08e-07	9.01e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—kidney cancer	3.08e-07	9e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—kidney cancer	3.07e-07	8.98e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—kidney cancer	3.07e-07	8.98e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	3.05e-07	8.93e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—kidney cancer	3.04e-07	8.9e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—kidney cancer	3.04e-07	8.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—kidney cancer	3e-07	8.77e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—kidney cancer	2.99e-07	8.75e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	2.98e-07	8.73e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—kidney cancer	2.98e-07	8.72e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	2.98e-07	8.71e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—kidney cancer	2.97e-07	8.69e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1A1—kidney cancer	2.96e-07	8.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—kidney cancer	2.95e-07	8.64e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—kidney cancer	2.95e-07	8.61e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—kidney cancer	2.94e-07	8.61e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ACHE—kidney cancer	2.94e-07	8.61e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—kidney cancer	2.93e-07	8.56e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—kidney cancer	2.92e-07	8.53e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—kidney cancer	2.91e-07	8.51e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—kidney cancer	2.9e-07	8.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—kidney cancer	2.9e-07	8.47e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK1—kidney cancer	2.89e-07	8.45e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1A1—kidney cancer	2.89e-07	8.44e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—kidney cancer	2.88e-07	8.43e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—kidney cancer	2.84e-07	8.31e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK1—kidney cancer	2.84e-07	8.3e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—kidney cancer	2.83e-07	8.28e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	2.82e-07	8.26e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—kidney cancer	2.82e-07	8.25e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SCARB1—kidney cancer	2.79e-07	8.15e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—kidney cancer	2.77e-07	8.09e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS1—kidney cancer	2.76e-07	8.07e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—kidney cancer	2.75e-07	8.05e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—kidney cancer	2.75e-07	8.04e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—kidney cancer	2.75e-07	8.03e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—kidney cancer	2.74e-07	8.02e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—kidney cancer	2.73e-07	7.99e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—kidney cancer	2.73e-07	7.98e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—kidney cancer	2.72e-07	7.96e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.72e-07	7.96e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—kidney cancer	2.71e-07	7.91e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PSMD7—kidney cancer	2.71e-07	7.91e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.7e-07	7.88e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK1—kidney cancer	2.69e-07	7.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	2.69e-07	7.86e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	2.69e-07	7.86e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—kidney cancer	2.68e-07	7.84e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—kidney cancer	2.67e-07	7.82e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—kidney cancer	2.65e-07	7.76e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—kidney cancer	2.64e-07	7.73e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—kidney cancer	2.62e-07	7.65e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BCHE—kidney cancer	2.56e-07	7.5e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—kidney cancer	2.54e-07	7.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	2.54e-07	7.44e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	2.54e-07	7.42e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.53e-07	7.41e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—kidney cancer	2.51e-07	7.33e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—kidney cancer	2.47e-07	7.23e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—kidney cancer	2.47e-07	7.22e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—kidney cancer	2.46e-07	7.2e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.45e-07	7.15e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.43e-07	7.1e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—kidney cancer	2.43e-07	7.09e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	2.42e-07	7.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—kidney cancer	2.4e-07	7.01e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—kidney cancer	2.38e-07	6.97e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—kidney cancer	2.34e-07	6.83e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	2.33e-07	6.82e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—kidney cancer	2.33e-07	6.8e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—kidney cancer	2.3e-07	6.73e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—kidney cancer	2.3e-07	6.73e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	2.29e-07	6.68e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—kidney cancer	2.27e-07	6.63e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—kidney cancer	2.26e-07	6.61e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—kidney cancer	2.26e-07	6.59e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.21e-07	6.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—kidney cancer	2.21e-07	6.45e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—kidney cancer	2.2e-07	6.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK1—kidney cancer	2.16e-07	6.31e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—kidney cancer	2.15e-07	6.29e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	2.1e-07	6.14e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.04e-07	5.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—kidney cancer	2.04e-07	5.96e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—kidney cancer	2.03e-07	5.94e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—kidney cancer	2.03e-07	5.93e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—kidney cancer	2.01e-07	5.88e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—kidney cancer	1.97e-07	5.76e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—kidney cancer	1.95e-07	5.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.93e-07	5.65e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.88e-07	5.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—kidney cancer	1.87e-07	5.47e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—kidney cancer	1.81e-07	5.3e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.78e-07	5.2e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—kidney cancer	1.76e-07	5.14e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—kidney cancer	1.72e-07	5.02e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—kidney cancer	1.72e-07	5.02e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—kidney cancer	1.6e-07	4.69e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—kidney cancer	1.53e-07	4.48e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—kidney cancer	1.5e-07	4.38e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—kidney cancer	1.43e-07	4.19e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—kidney cancer	1.4e-07	4.09e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—kidney cancer	1.33e-07	3.88e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.21e-07	3.54e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.08e-07	3.16e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.06e-07	3.09e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—kidney cancer	1.06e-07	3.09e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—kidney cancer	9.86e-08	2.88e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—kidney cancer	9.22e-08	2.7e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.5e-08	1.9e-06	CbGpPWpGaD
